After the Viox scandal, this would come as a big relief to pharmapsutical industry which had been taking a beating lately. (Albeit not in terms of revenues but goodwill).
According to two large ongoing studies, the Vytorin cholesterol fighter developed and sold by Merck has not been found to be linked to cancer or cancer deaths, it was revealed in a meeting in London.
According to Sir Peto,”There is no overall credible evidence of an increase in cancer”. Sir Peto is the professor of medical statistics and epidemiology at the University of Oxford.
However in contrast, there was a study conducted on 1,873 patients, called SEAS, a higher number of patients with thickened aortic valves receiving Vytorin developed cancer or died of cancer compared to those who recieved placebos.